Regulation of oxidative burst using LMWG-derived peptides and analogs
US6184203A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 5, 1998 |
| Grant date | Feb 6, 2001 |
| Priority date | — |
| Expiry date | Mar 5, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to optionally substituted, non-toxic peptides and derivatives capable of inhibiting superoxide production in phagocytic cells. The invention also relates to compositions and methods useful in inhibiting inflammation and in treating inflammatory disorders such as autoimmune disorders, gout, adult respiratory distress syndrome, asthma, myocardial infarction, and various dermatological disorders. The present invention contemplates compositions derived from low molecular weight GTP-binding proteins (LMWG), mastoparan, GAP proteins, and related peptides. The invention further contemplates compositions useful in inhibiting activation of NADPH oxidase or in promoting GDP/GTP exchange. Therapeutic compositions containing various inhibitors, and methods of using same, are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.